Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort ascending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete Mar 15, 2007 Sep 26, 2007
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn Nov 3, 2006
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Reimburse with clinical criteria and/or conditions Active Jun 25, 2020 Mar 24, 2021
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete Dec 20, 2016 Jun 20, 2017
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Do not reimburse Active Aug 25, 2020 Jun 23, 2021
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete Oct 27, 2015 May 19, 2016
Zenhale (inhalation aerosol) Mometasone furoate and formoterol Asthma Do not list Complete Feb 16, 2011 Sep 28, 2011
Zenhale Mometasone/formoterol Asthma List with clinical criteria and/or conditions Complete Jun 6, 2012 Dec 19, 2012
Zeldox Ziprasidone hydrochloride Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete Jan 10, 2008 Aug 14, 2008